Company CVAbout Jubilant Ingrevia Ltd 
Jubilant Ingrevia Ltd
Mid Cap
Pharmaceuticals & Drugs
Jubilant Ingrevia Limited (Formerly known as Jubilant LSI Limited) was incorporated as a Public Limited Company on 23 October 2019 in Uttar Pradesh. The name of Company was changed from 'Jubilant LSI Limited' to 'Jubilant Ingrevia Limited' effective October 16, 2020.
Company Coordinates
No Company Details Available
Capital StructureCapital Structure
Present Equity Capital
INR 15.93 Cr
Number of Shares
15.93 Cr
Face Value
INR 1.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
15-Feb-2021
15.93
15.93
158781139
1
Scheme of Arrangement
23-Oct-2019
5
0.05
500000
1
Subscriber to MOA
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
2.7138
Mutual Funds
Held by 17 Schemes (13.91%)
FIIs
Held by 109 FIIs (6.89%)
Promoter with highest holding
Spb Trustee Company Pl & Ss Trustee Company Pl (20.63%)
Highest Public shareholder
Dsp Small Cap Fund (9.52%)
Individual Investors Holdings
19.17%
Board of Directors
Management
Designation
Remuneration
Shyam S Bhartia
Chairman & Non Executive Dir.
0
Hari S Bhartia
Co-Chairman / Non Executive Di
0
S K Roongta
Independent Non Exe. Director
18.45 lacs
Sudha Pillai
Independent Non Exe. Director
16.65 lacs
ARUN SETH
Independent Non Exe. Director
15.9 lacs
Pradeep Banerjee
Independent Non Exe. Director
19.15 lacs
SIRAJ AZMAT CHAUDHRY
Independent Non Exe. Director
18.55 lacs
Ameeta Sonjoy
Independent Non Exe. Director
18.65 lacs
Priyavrat Bhartia
Non Executive Director
0
Arjun Shanker Bhartia
Non Executive Director
0
Rajesh Srivastava
Managing Director & CEO
6.52 cr
Mr. Deepak Jain
Managing Director & CEO
0
Mr. Chandan Singh Sengar
Whole Time Director & CEO
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
No Data Available for Finished Goods Segmentation
No Data Available
Stock DNARevenue and Profits:
Net Sales:
1,057 Cr
(Quarterly Results - Dec 2024)
Net Profit:
69 Cr
Pharmaceuticals & Drugs
INR 10,036 Cr (Mid Cap)
46.00
33
0.83%
0.23
6.24%
3.40
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
